Compare Expeditors International of Wshngtn Inc (EXPD) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Expeditors International of Wshngtn Inc trades at $193.74 (market cap $25.18B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3× Expeditors International of Wshngtn Inc's market cap, and Expeditors International of Wshngtn Inc pays the higher dividend (0.84%). Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 43 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| EXPD | REGN | |
|---|---|---|
Market Cap | $25.18B | $76.14B |
Volume | 1,003,557 | 500,239 |
Sector | Industrials | Health |
52-Week High | $194.12 | $852.03 |
52-Week Low | $113.13 | $557.73 |
Typical Hold Time | 43 Days | 107 Days |
Enterprise Value | $24.72B | $70.85B |
Dividend Yield | 0.84% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $190.85, down 0.5% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.03 surpassing the $1.69 estimate. Revenue for 2025 reached $11.07 billion, with a net income margin of 7.63% and robust ROE of 42.6%. Recent news highlights efficiency initiatives and resilient airfreight demand as positive catalysts.
The outlook is mixed; solid profitability and earnings momentum support upside, but the stock trades above the consensus price target of $179.43, with analysts predominantly neutral (63.64% Hold). Key risks include freight market volatility and execution challenges. Institutional activity shows mixed signals, with some firms increasing stakes while others reduce positions.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
